source
- UniQure to submit UK marketing application for Huntington's gene therapy AMT-130UniQure announced it will file a marketing application in the United Kingdom later this year for its gene therapy AMT-130 aimed at Huntington's disease. The filing follows a positive meeting with…
- FDA oncology panel votes against AstraZeneca's camizestrant trial, citing lack of meaningful benefitThe FDA's oncology advisory committee convened for the first time in about nine months and evaluated AstraZeneca's late-stage trial of its oral selective estrogen receptor degrader, camizestrant.…